exRNAdisease

Entry Detail

---



General Information

Database ID: exR0269813 RNA Name: hsa-miR-380-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101025056 End Site(bp): 101025077 External Links: hsa-miR-380-3p

Disease Information

Disease Name: Multiple Sclerosis Disease Category: Nervous System Diseases MeSH ID: D009103 Type: Diseases Category/Nervous System Diseases Alias: Sclerosis, Multiple//Sclerosis, Disseminated//Disseminated Sclerosis//MS (Multiple Sclerosis)//Multiple Sclerosis, Acute Fulminating

Expression Detail

GEO ID: GSE140106 Description: Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment Experimental Design: Fingolimod treatment Case Disease Type: Multiple Sclerosis Case Disease SubType: NA Case Sample: Fingolimod treated Multiple Sclerosis Control Sample: Untreated Number of Case: 27 Number of Control: 27 Number of Samples: 54

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AGFG1 chr2 227472152 227561214 + KPNA6 chr1 32108056 32176563 + KRAS chr12 25205246 25250936 - MEF2A chr15 99565417 99716466 + ZBTB21 chr21 41986831 42010387 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000712 chr16 68208276 68225678 + hsa_circ_0001723 chr7 91924202 91948826 + hsa_circ_0000711 chr16 68155889 68160513 + hsa_circ_0001740 chr7 117825700 117828459 + hsa_circ_0000744 chr17 15968183 15971435 - hsa_circ_0000552 chr14 71880664 71948928 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand DSCAM-AS1 chr21 40383083 40385358 + FGD5-AS1 chr3 14920347 14948424 - MCM3AP-AS1 chr21 46229196 46259390 + MIR4458HG chr5 8450701 8486930 + OIP5-AS1 chr15 41283990 41309737 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE140106 Sample Source: Blood Source Fraction: Exosome Platform: GPL11154 Method: NGS Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1907 Sample treatment protocol: Exosomes were isolated from 1 mL RNase A (37 °C for 10 min; 100 ng/ml; Qiagen, Australia) treated serum, by size exclusion chromatography (qEV iZONE Science). RNA Extract protocol: Serum exosomes were processed for RNA extraction using the Plasma/Serum Circulating & Exosomal RNA Purification Mini Kit (Norgen Biotek, Cat. 51000) according to the manufacturer's protocol. RNA library preparation protocol: Exosome RNA sequencing libraries were then constructed using the NEBNext Multiplex Small RNA Library Prep Kit for Illumina (BioLabs, New England) according to the manufacturer's instructions.

Reference

PMID: 31721043 Title: Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment Author: Ebrahimkhani S, Beadnall HN, Wang C, Suter CM, Barnett MH, Buckland ME, Vafaee F Journal: Mol Neurobiol. 2020 Feb;57(2):1245-1258. Description: we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy.